Renaissance Group LLC Sells 44,445 Shares of Afya Limited $AFYA

Renaissance Group LLC decreased its position in shares of Afya Limited (NASDAQ:AFYA) by 43.5% during the third quarter, Holdings Channel.com reports. The fund owned 57,815 shares of the company’s stock after selling 44,445 shares during the quarter. Renaissance Group LLC’s holdings in Afya were worth $902,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in AFYA. Arrowstreet Capital Limited Partnership increased its stake in shares of Afya by 5.6% in the second quarter. Arrowstreet Capital Limited Partnership now owns 68,169 shares of the company’s stock worth $1,217,000 after purchasing an additional 3,626 shares in the last quarter. Dodge & Cox boosted its holdings in Afya by 12.8% in the 2nd quarter. Dodge & Cox now owns 35,262 shares of the company’s stock worth $630,000 after buying an additional 4,000 shares during the period. Militia Capital Partners LP purchased a new stake in Afya in the 2nd quarter worth $71,000. Quantbot Technologies LP bought a new stake in Afya during the second quarter valued at about $117,000. Finally, Cerity Partners LLC raised its holdings in Afya by 34.3% during the second quarter. Cerity Partners LLC now owns 35,688 shares of the company’s stock valued at $637,000 after acquiring an additional 9,120 shares during the period. Hedge funds and other institutional investors own 88.02% of the company’s stock.

Afya Stock Performance

NASDAQ:AFYA opened at $15.43 on Friday. The company has a market cap of $1.45 billion, a price-to-earnings ratio of 11.10, a PEG ratio of 0.57 and a beta of 0.50. Afya Limited has a 1 year low of $13.12 and a 1 year high of $19.90. The stock’s 50 day simple moving average is $14.78 and its two-hundred day simple moving average is $14.88. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.98 and a quick ratio of 0.98.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Zacks Research lowered Afya from a “hold” rating to a “strong sell” rating in a research note on Friday, January 9th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $22.00 price target (down from $24.50) on shares of Afya in a report on Wednesday, January 7th. UBS Group reaffirmed a “neutral” rating and set a $16.00 price objective (down from $18.00) on shares of Afya in a report on Friday, January 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Afya in a report on Wednesday, January 21st. Finally, Sanford C. Bernstein upgraded shares of Afya to a “market perform” rating in a research report on Friday, January 16th. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Afya currently has a consensus rating of “Hold” and a consensus target price of $17.38.

Afya Company Profile

Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.

At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.